EGFR and glioblastoma: For ex vivo cultures, we selected three primary patient-derived GBM lines, including GBM6 and GBM39, which predominantly express EGFRvIII, and GBM12, which contains a point mutation (G719A) in the EGFR tyrosine kinase domain.